Augmented insights and minor adjustments to the role of adhesin proteins in Acinetobacter baumannii infections
Dongmei Xiao, Huaichang Zhong, Qionghua Huang, Mei Cha

Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsEscherichia coli research studies · Antibiotic Resistance in Bacteria · Vibrio bacteria research studies
LETTER
Pereira et al. (1) investigated the role of adhesin proteins in controlling Acinetobacter baumannii infections, identifying potential therapeutic targets through an analysis of studies involving bioinformatics, immunization, and antibody-mediated therapies. Pereira et al. (1) provided valuable insights and reference points for the development of new treatments and preventive strategies against multidrug-resistant A. baumannii infections, thereby aiding researchers and clinicians in exploring alternative solutions, such as vaccines and immunotherapies. We read their article with great interest and would like to offer some comments in light of our knowledge.
First, Pereira et al. (1) argued that since A. baumannii was responsible for nosocomial infections, developing a vaccine against this pathogen may not be feasible. This perspective is likely based on the complex biological characteristics of the pathogen and the limitations of current technology. Acinetobacter baumannii is a highly drug-resistant pathogen that can rapidly adapt to environmental changes and develop resistance, which poses significant challenges for vaccine development. Moreover, its diverse strains and complex pathogenic mechanisms further increase the difficulty of developing a vaccine.
In fact, many studies have emphasized that vaccination may be a more effective intervention measure for preventing Acinetobacter baumannii infections (2, 3). Vaccination, as a preventive measure, can provide immune protection before the infection of pathogens, thereby reducing the incidence and severity of infections. Vaccination can also decrease the need for antibiotics, which in turn reduces the occurrence of antimicrobial resistance. Therefore, despite the technical challenges, vaccine development remains a worthwhile endeavor.
Second, Pereira et al. (1) pointed out that the study by Jackson-Litteken et al. (4) uncovered the significance of a novel invasin-like adhesin (InvL) in promoting bacterial adhesion and invasion in urinary tract epithelial cells in vitro. We carefully read the research report by Jackson-Litteken et al. (4) and found that they mentioned the role of InvL in bacterial adhesion to urinary tract epithelial cells in their study, but did not observe any InvL-mediated internalization of bacteria into the cells. The claim that InvL has invasive functions is not supported by the research findings of Jackson-Litteken et al. (4). Therefore, a more accurate description would be that Jackson-Litteken et al. (4) confirmed the role of InvL in bacterial adhesion, not invasion.
Third, Pereira et al. pointed out that therapies against A. baumannii should target adhesin proteins. We believe that this statement requires some supplementation and clarification. Therapeutic strategies against A. baumannii can indeed include targeting adhesin proteins, as these proteins play a key role in the bacterial infection process. However, adhesin proteins are just one of several potential therapeutic targets. In addition to adhesin proteins, A. baumannii secretes other virulence factors, such as phospholipase C and glycoprotease CpaA (5, 6), which can also serve as therapeutic targets. Therefore, when developing therapeutic strategies against this pathogen, multiple other targets should be considered. This approach could provide a more comprehensive solution to address the complexity and drug resistance of A. baumannii.
Finally, we noticed a minor discrepancy in the article by Pereira et al. (1). In the abstract of their article, they stated that they conducted a systematic review of A. baumannii adhesin research from the last decade 2013–2023. However, it should be clarified that their review actually covered the period from January 2013 to July 2024.
In conclusion, Pereira et al. (1) have provided valuable insights into the role of adhesin proteins in controlling Acinetobacter baumannii infections. In this letter, we have offered additional perspectives and made minor corrections to certain points in their article. We hope that these efforts will help readers gain a better and more comprehensive understanding of the work by Pereira et al. (1).
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1Pereira IL, Hartwig DD. 2025. Unveiling the role of adhesin proteins in controlling Acinetobacter baumannii infections: a systematic review. Infect Immun 93:e 0034824. doi:10.1128/iai.00348-2439772848 PMC 11834437 · doi ↗ · pubmed ↗
- 2Ma C, Mc Clean S. 2021. Mapping global prevalence of Acinetobacter baumannii and recent vaccine development to tackle it. Vaccines 9:570. doi:10.3390/vaccines 906057034205838 PMC 8226933 · doi ↗ · pubmed ↗
- 3Venkataraman R, Yadav U, Shivalingegowda RK, Shrestha Y. 2023. Vaccination strategies to combat nosocomial infections. Vacunas 24:60–67. doi:10.1016/j.vacun.2022.11.001 · doi ↗
- 4Jackson-Litteken CD, Di Venanzio G, Le N-H, Scott NE, Djahanschiri B, Distel JS, Pardue EJ, Ebersberger I, Feldman MF. 2022. Inv L, an invasin-like adhesin, is a type II secretion system substrate required for Acinetobacter baumannii uropathogenesis. M Bio 13:e 0025822. doi:10.1128/mbio.00258-2235638734 PMC 9245377 · doi ↗ · pubmed ↗
- 5Zhou JX, Feng DY, Li X, Zhu JX, Wu WB, Zhang TT. 2023. Advances in research on virulence factors of Acinetobacter baumannii and their potential as novel therapeutic targets. J Appl Microbiol 134:lxac 089. doi:10.1093/jambio/lxac 08936597783 · doi ↗ · pubmed ↗
- 6Waack U, Warnock M, Yee A, Huttinger Z, Smith S, Kumar A, Deroux A, Ginsburg D, Mobley HLT, Lawrence DA, Sandkvist M. 2018. Cpa A is a glycan-specific adamalysin-like protease secreted by Acinetobacter baumannii that inactivates coagulation factor XII. M Bio 9:e 01606-18. doi:10.1128/m Bio.01606-1830563903 PMC 6299215 · doi ↗ · pubmed ↗
